IQVIA
Combines healthcare intelligence and commercial technology with global clinical research services.
Something off on this page? Send us feedback.
Profile
Provides healthcare data, analytics, cloud software, consulting, contract sales, and patient engagement through Commercial Solutions, while Research & Development Solutions manages clinical trials, laboratories, regulatory support, and real-world research. Revenue is weighted toward outsourced R&D, with operations spanning the Americas, Europe and Africa, and Asia-Pacific.
Runs complementary Commercial Solutions and Research & Development Solutions businesses for life-sciences and healthcare clients. Commercial Solutions sells healthcare information, advanced analytics, cloud software, consulting, contract sales, and patient-engagement services. Research & Development Solutions manages outsourced clinical development, including study design, site start-up, patient recruitment, monitoring, regulatory support, laboratories, and real-world research.
Combines proprietary health datasets with technology and therapeutic expertise to inform commercial decisions and make trial planning and recruitment more targeted. Subscription information and cloud software sit alongside project-based research and outsourced engagement services, linking data products with execution across the drug lifecycle.
Serves clients in the Americas, Europe and Africa, and Asia-Pacific. Operations span more than 100 countries and depend on privacy-compliant access to health data and adherence to clinical-trial and healthcare regulations across jurisdictions.
Company facts
Key statistics
Year to date +16.1% · Average volume (30d) 1.4M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 29, 2026 | RBC Capital | Reiterate | Outperform | $270 | $247 | |
| Jul 29, 2026 | BMO Capital | Reiterate | Outperform | $250 | $270 | |
| Jul 29, 2026 | Robert W. Baird | Target | $249 | $287 | ||
| Jul 13, 2026 | Mizuho Securities | Target | $215 | $230 | ||
| Jul 9, 2026 | Deutsche Bank | Target | $270 | $240 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026Q2 FY26 | $3.03 | $3.15 | +4.0% | $4.30B | $4.37B | +1.5% | +1.90% |
| May 5, 2026Q1 FY26 | $2.82 | $2.90 | +2.8% | $4.10B | $4.15B | +1.2% | +0.03% |
| Feb 5, 2026Q4 FY25 | $3.40 | $3.42 | +0.6% | $4.24B | $4.36B | +2.9% | +3.61% |
| Oct 28, 2025Q3 FY25 | $2.98 | $3.00 | +0.7% | $4.08B | $4.10B | +0.5% | −0.14% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.83B | $4.02B | $4.10B | $4.36B | $4.15B | $4.37B | |
| Gross profit | $1.30B | $1.32B | $1.37B | $292.0M | $1.36B | $1.44B | |
| Operating income | $496.0M | $506.0M | $553.0M | $732.0M | $514.0M | $506.0M | |
| Net income | $249.0M | $266.0M | $331.0M | $514.0M | $274.0M | $256.0M | |
| Diluted EPS | $1.40 | $1.54 | $1.93 | $2.99 | $1.61 | $1.53 | |
| Gross margin | 33.9% | 32.9% | 33.5% | 6.7% | 32.6% | 32.9% | |
| Operating margin | 13.0% | 12.6% | 13.5% | 16.8% | 12.4% | 11.6% |
Fiscal years (4-quarter sums)FY21 $13.87B · FY22 $14.42B · FY23 $14.98B · FY24 $15.41B · FY25 $16.31B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $2.08B · Total debt $16.24B · Total assets $29.88B · Shareholders' equity $6.17B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 164.60M · Float 156.25M · 94.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 14.55M | 8.84% | 13F | Aug 7, 2026 |
| Harris Associates L P | 12.18M | 7.40% | 13F | Aug 14, 2026 |
| Vanguard Capital Management LLC | 10.91M | 6.63% | 13F | Aug 13, 2026 |
| State Street Corp | 7.51M | 4.56% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 7.50M | 4.56% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 31, 2026 | Bhavik Patel | officer: See Remarks | −1,855 | $235.27 |
| Aug 3, 2026 | W. Richard Staub | officer: See Remarks | −5,500 | $232.68 |
| Jul 29, 2026 | Ari Bousbib | director, officer: See Remarks | −106,279 | $245.51 |
| Jul 29, 2026 | Keriann Cherofsky | officer: See Remarks | −558 | $245.21 |
| Jul 29, 2026 | Eric Sherbet | officer: See Remarks | −5,000 | $249.16 |
Peers
- ICON
Largest pure-play CRO rival; head-to-head in global Phase I–IV trial services.
- Thermo Fisher Scientific
PPD division competes head-to-head in global Phase I–IV clinical research.
- Veeva Systems
Life sciences SaaS leader challenging IQVIA's commercial CRM and clinical data.
- Medpace
Fast-growing mid-tier CRO; wins small biotech mandates via full-service depth.
- Charles River Laboratories
Premier preclinical CRO; discovery and safety assessment overlap with IQVIA.
- Fortrea
Mid-tier CRO spun from Labcorp; Phase I–IV in oncology and rare disease.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| IQVIA | $261.75 | +0.03% | $43.08B | 32.5 | 19.2 | 2.5 | +8.7% |
| ICON | $170.02 | +0.07% | $13.02B | 39.9 | 15.2 | 1.6 | +2.3% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Veeva Systems | $276.99 | +0.12% | $44.95B | 45.5 | 29.2 | 13.0 | +17.6% |
| Medpace | $600.65 | +0.03% | $16.77B | 35.2 | 32.7 | 6.0 | +17.2% |
| Charles River Laboratories | $291.50 | +0.04% | $14.04B | — | 23.7 | 3.5 | −2.7% |
| Fortrea | $18.89 | +0.51% | $1.79B | — | 19.5 | 0.7 | −4.5% |
| Median | 37.5 | 23.7 | 4.3 | +6.4% |